Microfluidics technology for physiologically relevant assays

Jeff Jensen, CEO of Fluxion Biosciences describes how microfluidics technology fuels drug discovery through physiologically relevant cell-based models

Related Keywords

United States ,American ,Acta Pharmaceutica Sinica ,Jeff Jensen ,Stem Cell Research Therapy ,Drug Administration ,Editorial Article ,Fluxion Biosciences ,Modernization Act ,Physiology Cell ,Reviews Drug Discovery ,Analytical Chemistry ,Cell Research ,Catarina Rap ,Microfluidics Technology Provides Physiologically Relevant Cell Based Models For High Throughput Drug Discovery Selectscience Cart Therapy ,Microfluidic Technology ,Cellular Interaction ,